高肿瘤负荷转移性去势抵抗性前列腺癌应答患者中[177Lu]Lu-PSMA-617的延长治疗
该研究纳入26例标准[177Lu]Lu-PSMA-617放射配体治疗(4-6周期)后仍为高肿瘤负荷(按CHAARTED标准)且无替代治疗方案的转移性去势抵抗性前列腺癌患者,给予额外周期治疗,中位达10(范围7-16)周期,每周期平均活度7.4±0.9 GBq。延长治疗期间21/26(81%)患者PSA进一步下降33±28%,5/26(19%)患者PSA升高;中位无进展生存期19(95%CI:15-23)个月,总生存期29(95%CI:18-40)个月。作者认为延长放射配体治疗是可行的治疗选择,改善的生存和可接受的安全性 warrant 进一步研究。
要点
- 标准[177Lu]Lu-PSMA-617治疗6周期后高肿瘤负荷患者可接受额外周期,中位达10周期。
- 延长治疗期间81%(21/26)患者PSA进一步下降33±28%,19%(5/26)患者PSA升高。
- 延长治疗期间≥3级血液学毒性4/26(15%),随访中≥3级肾毒性1/26(4%)。
核心结论
- 作者认为,对于完成标准6周期[177Lu]Lu-PSMA-617治疗后仍为高肿瘤负荷的患者,延长放射配体治疗是可行的治疗选择。
- 作者认为,改善的生存和可接受的安全性 warrant 在选定患者中进一步研究额外周期的概念。
研究设计与样本
- 研究纳入26例标准放射配体治疗(4-6周期,每周期6.0-7.4 GBq [177Lu]Lu-PSMA-617)后按CHAARTED标准仍为高肿瘤负荷且无替代治疗方案的转移性去势抵抗性前列腺癌患者。
- 患者接受额外放射配体治疗周期,中位达10(范围7-16)周期,每周期平均活度7.4±0.9 GBq。
- 每2-3周期或临床怀疑疾病进展或基于PSA值变化(按PCWG3标准)行[68Ga]Ga-PSMA-11 PET/CT评估应答。
- 毒性通过常规血液检查(包括血细胞计数、肝肾功能)按CTCAE v5.0标准分级。
- 生存结局采用Kaplan-Meier法计算。
主要发现
- 延长治疗期间,21/26(81%)患者观察到PSA进一步下降33±28%,5/26(19%)患者PSA升高。
- 在21例对延长周期有初始应答(PR或SD)的患者中,11例因疾病进展停止治疗,6例(23%)达到低肿瘤负荷残留病灶。
- 2例(8%)患者死亡时未显示进展,2例(8%)患者仍在治疗中。
- 中位无进展生存期为19(95%CI:15-23)个月,总生存期为29(95%CI:18-40)个月。
- 延长治疗期间≥3级血液学毒性发生于4/26(15%)患者,随访期间观察到≥3级肾毒性1/26(4%)患者。
临床怎么用
- 作者认为,延长放射配体治疗是完成标准6周期[177Lu]Lu-PSMA-617治疗后仍为高肿瘤负荷患者的可行治疗选择。
- 作者认为,改善的生存和可接受的安全性 warrant 在选定患者中进一步研究额外周期的概念。
局限性
- 作者指出,改善的生存和可接受的安全性 warrant 进一步研究额外周期的概念。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The currently used scheme for radioligand therapy (RLT) of patients with metastatic castration-resistant prostate cancer (mCRPC) consists of 4-6 cycles of 6.0-7.4 GBq [177Lu]Lu-PSMA-617 each. This standard treatment scheme has proved safe and effective resulting in objective response in most patients with no significant toxicity. Many patients, however, show high-volume residual tumor burden after the sixth cycle and may benefit from treatment continuation. Extended treatment with additional cycles has been withheld due to concerns on potential increased toxicity. METHODS: Twenty-six patients with high-volume residual tumor burden (according to CHAARTED) after standard RLT with [177Lu]Lu-PSMA-617 and no alternative treatment option received additional RLT cycles reaching a median of 10 (range 7-16) cycles with a mean activity of 7.4 ± 0.9 GBq per cycle. Response assessment with [68Ga]Ga-PSMA-11 PET/CT was done every 2-3 cycles or if disease progression was clinically suspected or based on change in PSA value (according to the PCWG3 criteria). Toxicity was measured using routine blood work up including blood counts, liver and renal function, and was graded according to CTCAE v5.0 criteria. Survival outcome was calculated based on the Kaplan-Meier method. RESULTS: Further PSA decline of 33 ± 28% during the extended treatment was observed in 21/26 (81%) patients, whereas 5/26 (19%) patients showed a PSA increase; correspondingly in 11/21 patients with an initial response (PR or SD) to extended cycles, treatment was discontinued due to progressive disease, whereas six (23%) patients achieved low-volume residual disease. Two (8%) patients died without showing progression, and two (8%) patients are still under therapy. The median progression-free survival was 19 (95% CI: 15-23) months, and the overall survival was 29 (95% CI: 18-40) months. Grade ≥ 3 hematological toxicities occurred in 4/26 (15%) patients during treatment extension, and nephrotoxicity (grade ≥ 3) was observed in 1/26 (4%) patient during the follow-up. CONCLUSION: Extended radioligand therapy is a feasible treatment option in patients with high-volume residual tumor after the completion of standard treatment with six cycles of [177Lu]Lu-PSMA-617. Improved survival and the acceptable safety profile warrant further investigation of the concept of additional cycles in selected patients.
引用
- Mader N, Nguyen Ngoc C, Kirkgöze B, et al. Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2023. PMID: 36702927. doi:10.1007/s00259-023-06119-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。